{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:00:35Z","timestamp":1790830835620,"version":"4.1.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004772","name":"Natural Science Foundation of Ningxia","doi-asserted-by":"publisher","award":["2026AAC030399"],"award-info":[{"award-number":["2026AAC030399"]}],"id":[{"id":"10.13039\/501100004772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To explore whether distinct clinical features can serve as predictive indicators for the underlying NB and examine the neurodevelopmental outcomes in children diagnosed with opsoclonus-myoclonus syndrome (OMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively enrolled children with a definitive diagnosis of OMS at Peking University First Hospital between January 2010 to January 2025. Demographic data, clinical characteristics were collected to compare based on with or without tumor. Neurodevelopmental outcomes were classified based on adaptive behavior assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-three children were totally included, including 30 with NB and 43 without NB. 52 children (71%) had neurological signs onset concentrated between 1 and 2\u202fyears of age. There was significant difference in the composition ratio of initial symptoms between the two groups of OMS patients. The proportion of opsoclonus as the initial symptom in the OMS with NB group (20%) was higher than that in the OMS without NB group (2%). 48 patients with neurological remission underwent assessment of adaptive behavior. By the last follow-up, 28 (58%) patients had good adaptive behavior, and 20 (42%) patients had poor adaptive behavior. The main variables influencing the neurodevelopmental prognosis in OMS patients, ranked from highest to lowest importance, are as follows: chemotherapy, rituximab, myoclonus at onset, immunotherapy initiation, tumor, age at onset, gender, ataxia at onset, OMS severity at onset, opsoclonus at onset, and ataxia at onset. The multivariate logistic regression model further confirmed that myoclonus at onset (OR\u202f=\u202f14.33, 95% CI: 1.77\u2013116.4,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.01) was an independent risk factor for poor outcomes, whereas neuroblastoma (OR\u202f=\u202f0.11, 95% CI: 0.02\u20130.68,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.02) and chemotherapy (OR\u202f=\u202f0.07, 95% CI: 0.01\u20130.58,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.02) were independent protective factors. The ROC curve yielded an AUC of 0.856, indicating good discriminative ability of the model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Opsoclonus as the initial symptom may be a predictive indicator for the underlying NB. With NB and chemotherapy are the key factors for the favorable neurodevelopmental prognosis of OMS patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1892635","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:49:00Z","timestamp":1790830140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of underlying neuroblastoma and neurodevelopmental outcomes in children with opsoclonus-myoclonus syndrome: a retrospective cohort study in China"],"prefix":"10.3389","volume":"17","author":[{"given":"Qing","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Children's Medical Center, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Children's Medical Center, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Children's Medical Center, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Children's Medical Center, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Children's Medical Center, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.braindev.2014.10.010","article-title":"A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children","volume":"37","author":"Hasegawa","year":"2015","journal-title":"Brain Dev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.canlet.2005.01.051","article-title":"Opsoclonus myoclonus syndrome in neuroblastoma: a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004","volume":"228","author":"Matthay","year":"2004","journal-title":"Cancer Lett"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/pbc.22226","article-title":"Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up","volume":"53","author":"Catsman-Berrevoets","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1542\/peds.2010-3114","article-title":"Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life","volume":"128","author":"Brunklaus","year":"2011","journal-title":"Pediatrics"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jneuroim.2018.04.007","article-title":"Relation of intrathecal oligoclonal band production to inflammatory mediator and immunotherapy response in 208 children with OMS","volume":"321","author":"Pranzatelli","year":"2018","journal-title":"J Neuroimmunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e27097","DOI":"10.1002\/pbc.27097","article-title":"Multifactorial analysis of opsoclonus-myoclonus syndrome etiology (\"tumor\" vs. \"no tumor\") in a cohort of 356 US children","volume":"65","author":"Pranzatelli","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3389\/fneur.2017.00468","article-title":"Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study","volume":"8","author":"Pranzatelli","year":"2017","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/1043454204272560","article-title":"Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome","volume":"22","author":"Tate","year":"2005","journal-title":"J Pediatr Oncol Nurs"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"744041","DOI":"10.3389\/fneur.2021.744041","article-title":"Clinical analysis of Pediatric opsoclonus-myoclonus syndrome in one of the National Children's medical Center in China","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.braindev.2017.05.001","article-title":"Childhood opsoclonus-myoclonus syndrome: A case series from Tunisia","volume":"39","author":"Ben","year":"2017","journal-title":"Brain Dev"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4103\/aian.AIAN_101_18","article-title":"Clinical profile, prognostic indicators, and therapeutic outcomes of pediatric opsoclonus-myoclonus-ataxia syndrome: a single-center experience from South India","volume":"22","author":"Muthusamy","year":"2019","journal-title":"Ann Indian Acad Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/14737175.2016.1176914","article-title":"Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment","volume":"16","author":"Blaes","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/mpo.1138","article-title":"Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the children's Cancer group study","volume":"36","author":"Rudnick","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/ana.410350607","article-title":"Course and outcome of acute cerebellar ataxia","volume":"35","author":"Connolly","year":"1994","journal-title":"Ann Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejpn.2009.03.002","article-title":"A prospective study of the presentation and management of dancing eye syndrome\/opsoclonus-myoclonus syndrome in the United Kingdom","volume":"14","author":"Pang","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.22038\/AOJNMB.2022.65833.1459","article-title":"Neuroblastoma-related severe hypoperfusion in the cerebellum of an infant: A case of opsoclonus-myoclonus syndrome","volume":"11","author":"Takenaka","year":"2023","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/pin.12591","article-title":"Clinicopathological features of neuroblastic tumors with opsoclonus-myoclonus-ataxia syndrome: follicular structure predicts a better neurological outcome","volume":"67","author":"Fukushima","year":"2017","journal-title":"Pathol Int"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"054","DOI":"10.1055\/s-0035-1564714","article-title":"Early detection and treatment of neuroblastic tumor with opsoclonus-myoclonus syndrome improve neurological outcome: a review of five cases at a single institution in Japan","volume":"26","author":"Takama","year":"2016","journal-title":"Eur J Pediatr Surg"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/s0022-3476(06)80167-8","article-title":"Long-term outcome in children with opsoclonusmyoclonus and ataxia and coincident neuroblastoma","volume":"125","author":"Koh","year":"1994","journal-title":"J Pediatr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1200\/JCO.2008.17.9184","article-title":"Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the international neuroblastoma risk group database","volume":"27","author":"Bagatell","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1200\/JCO.21.00278","article-title":"Revised neuroblastoma risk classification system: a report from the children's oncology group","volume":"39","author":"Irwin","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/08880018.2017.1373315","article-title":"Treatment and survival of childhood neuroblastoma: evidence from a population-based study in the United States","volume":"34","author":"Coughlan","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1212\/wnl.62.9.1526","article-title":"B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes","volume":"62","author":"Pranzatelli","year":"2004","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2009.03.006","article-title":"Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome","volume":"210","author":"F\u00fchlhuber","year":"2009","journal-title":"J Neuroimmunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1177\/0883073814549581","article-title":"Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS)","volume":"30","author":"Mitchell","year":"2015","journal-title":"J Child Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pediatrneurol.2017.03.011","article-title":"Opsoclonus-myoclonus syndrome: a new era of improved prognosis?","volume":"72","author":"Galstyan","year":"2017","journal-title":"Pediatr Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1892635\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:49:10Z","timestamp":1790830150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1892635\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":26,"alternative-id":["10.3389\/fneur.2026.1892635"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1892635","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1892635"}}